Sinopharm 
Welcome,         Profile    Billing    Logout  
 25 Products   0 Diseases   25 Products   112 Trials   13941 News 


«12345678910111213...224225»
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Review, Journal:  Vitamin D: A key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants. (Pubmed Central) -  Nov 13, 2024   
    Therefore, large-scale randomized trials are required to reach a definitive conclusion. A bibliometric analysis of publications related to vitamin D, immunity, and COVID-19 revealed a significant increase in research activity in this area, particularly in 2020-2024, underscoring the growing recognition of vitamin D's potential role in the context of the pandemic.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Preclinical, Journal:  Design and biological evaluation of candidate drugs against zoonotic porcine deltacoronavirus (PDCoV). (Pubmed Central) -  Nov 13, 2024   
    Compound T1, with an isobutyl at the P2 site, displayed improved anti-PDCoV activity in vitro (cell infection model) and in vivo (embryonated chicken egg infection model), and therefore is a potential candidate drug to combat PDCoV. Together, our results identify the substrate-binding mode and substrate specificity of PDCoV 3CLpro, providing insight into the optimization of Nirmatrelvir as an antiviral therapeutic agent against PDCoV.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Clinical data, Journal:  Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System. (Pubmed Central) -  Nov 13, 2024   
    PREDICT96-ALI is able to distinguish clinically efficacious antiviral therapies like remdesivir and nirmatrelvir from promising lead compounds that do not show clinical efficacy. Importantly, results from this proof-of-concept study track with known clinical outcomes, demonstrate the feasibility of this technology as a prognostic drug discovery tool.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
    Journal:  The binding mechanism of failed, in processing and succeed inhibitors target SARS-CoV-2 main protease. (Pubmed Central) -  Nov 13, 2024   
    By gaining insights into the dynamics, we can potentially elucidate why lopinavir/ritonavir, initially considered promising, failed to effectively treat COVID-19. Furthermore, understanding the mechanistic aspects of N3 and NMV inhibition on SCM not only contributes to rational drug discovery against COVID-19 but also aids future studies on the catalytic mechanisms of main proteases in other novel coronaviruses.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Retrospective data, Journal:  Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea. (Pubmed Central) -  Nov 5, 2024   
    In conclusion, in this population of CLL and iB-NHL at high risk for poor response to vaccination, the modern management strategy that included PrEP with tixagevimab and cilgavimab and treatment with antiviral drugs resulted in low rates of severe COVID infection and death. Nirmatrelvir/ritonavir and molnupiravir are effective in preventing progression to severe disease in elderly adults with COVID-19.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Cost-Effectiveness Analysis of Paxlovid () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3080;    
    In conclusion, our study demonstrated an additive interaction between nirmatrelvir-ritonavir and complete vaccination on post-acute outcomes, suggesting greater long-term benefits of the antiviral for fully vaccinated individuals compared to not fully vaccinated patients. Our results suggests that Paxlovid is cost-effective compared to SoC for patients at high risk for severe COVID-19 from a health sector perspective in Portugal.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Requirements to Ensure Patient Safety Through Paxlovid () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_255;    
    This study suggests that utilization of nirmatrelvir/ritonavir is cost-effective compared to SoC for most patient groups, and especially for patients older than 70 years. Paxlovid
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis. (Pubmed Central) -  Oct 30, 2024   
    Paxlovid Furthermore, this study examines the published literature about the pharmacological interventions for the novel coronavirus disease 2019 (COVID-19), explicitly focusing on the safety and effectiveness of different medications such as Remdesivir (marketed as Veklury
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients. (Pubmed Central) -  Oct 30, 2024   
    Higher age and comorbidity burden were significantly associated with a higher likelihood of receiving medications that are "Contraindicated" with nirmatrelvir/ritonavir. In the evolving COVID-19 era, these findings provide insights into patients hospitalized for COVID-19, and the polypharmacy evaluations that clinicians may encounter when selecting among DAAs to manage COVID-19.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Organising pneumonia due to inadequately cleared COVID-19 infection while on rituximab. (Pubmed Central) -  Oct 27, 2024   
    It was thought that he did not clear his prior COVID-19 infection due to his immunocompromised state while taking rituximab. On recommendation of infectious disease, he was treated with a prolonged course of nirmatrelvir/ritonavir, remdesivir and corticosteroids with significant symptom improvement.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal, Adverse events:  Pharmacovigilance of Drug-Drug Interactions with Nirmatrelvir/Ritonavir. (Pubmed Central) -  Oct 27, 2024   
    On recommendation of infectious disease, he was treated with a prolonged course of nirmatrelvir/ritonavir, remdesivir and corticosteroids with significant symptom improvement. Low reporting rates of DDIs support the potential for NMV/r treatment to be safely managed with careful use of available drug interaction resources to aid in risk mitigation.
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
    Retrospective data, Journal:  The effect of COVID-19 vaccination on symptomatic infection and related symptoms among preterm-born children aged 3-7 years in China. (Pubmed Central) -  Oct 26, 2024   
    Likewise, COVID-19 vaccination was associated with a decline in the risk of pneumonia (odds ratio [OR]?=?0.318; 95% CI 0.110, 0.913), fever (RR?=?0.710; 95% CI 0.635, 0.794), high fever (RR?=?0.542; 95% CI 0.297, 0.988), sore throat (OR?=?0.304; 95% CI 0.139, 0.664), and persistent symptoms (RR?=?0.425; 95% CI 0.182, 0.993). Immunization with inactivated vaccines BBIBP-CorV and CoronaVac provides protection against symptomatic COVID-19 for preterm-born children 3-7 years.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Review, Journal:  Emerging small-molecule antiviral agents in long COVID prevention. (Pubmed Central) -  Oct 24, 2024   
    Recent evidence indicated that early antiviral intervention-particularly with small-molecule drugs such as Metformin, Ensitrelvir, Molnupiravir, and Nirmatrelvir-may effectively reduce the incidence of long COVID. This underscored the promising role of small-molecule compounds in mitigating long-term COVID-19 consequences, offering a novel preventive strategy against long COVID and its extensive impacts on patients.
  • ||||||||||  Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Review, Journal, Real-world evidence, Real-world effectiveness, Real-world:  Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review. (Pubmed Central) -  Oct 23, 2024   
    This underscored the promising role of small-molecule compounds in mitigating long-term COVID-19 consequences, offering a novel preventive strategy against long COVID and its extensive impacts on patients. This systematic literature review suggests continued effectiveness of sotrovimab in preventing severe clinical outcomes during BA.2 and BA.5 predominance, both against active/untreated comparators and compared with BA.1 predominance.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Two Cases of Reactivated TB developed in Patients with Outpatient Treatment for COVID-19 Infection (SAPPHIRE; B1F) -  Oct 21, 2024 - Abstract #KATRDIC2024KATRDIC_496;    
    Ten days ago, he was diagnosed COVID-19 and treated with Paxlovid in outpatient clinic...In fact, he was told a possibility of TB due to abnormal infiltrations at the left upper lobe in other hospital a few months ago and there were no positive results for M.TB at that time. Conclusion The currents cases reveal the evidence of a potential role of COVID-19 on TB reactivation.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years. (Pubmed Central) -  Oct 18, 2024   
    The antiviral group also exhibited a reduced risk of individual secondary outcomes, including emergency department visits (HR 0.780, 95% CI, 0.738-0.825), hospitalization (HR 0.755, 95% CI, 0.715-0.840), and mortality (HR 0.297, 95% CI, 0.147-0.600). Oral antiviral agents were associated with lower risks of all-cause emergency department visits, hospitalizations, and mortality in non-hospitalized COVID-19 patients aged <60?years.
  • ||||||||||  romlusevimab (BRII-198) / Brii Biosci, amubarvimab (BRII-196) / Brii Biosci
    Journal:  Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial. (Pubmed Central) -  Oct 14, 2024   
    Viral rebound was defined as RNA ?3 and ?0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ?2 days after initial symptom improvement. There was no difference in viral rebound (?5%/arm) (analysis population n=713) or symptom rebound among participants who initially improved (hazard ratio 0.95 (95% CI 0.52, 1.75, analysis population) n=574); <1% had both viral/symptom rebound.
  • ||||||||||  Immunogenicity of COVID-19 mRNA, Viral Vector, and Inactivated Virus Vaccines Regimens (Convention Center - Hall I-1 (1st Floor); In-Person-Only) -  Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1985;    
    Participants received COVID-19 mRNA vaccines (Comirnaty, Pfizer/BioNTech; Spikevax, Moderna), non-replicating viral vector vaccines (Jcovden, Johnson & Johnson/Janssen; Vaxzevria, Oxford/AstraZeneca), or inactivated vaccines (Covilo, Sinopharm; CoronaVac, Sinovac)...Anti-S IgG antibody responses to COVID-19 vaccines offered through national vaccination programs differed significantly in immunogenicity, based on vaccine platform. These data can help inform future public health decisions.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, BioNTech, Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
    Type of vaccine received and clinical severity in patients with two doses of COVID-19 immunization (Convention Center - Hall I-1 (1st Floor); In-Person-Only) -  Oct 11, 2024 - Abstract #ASTMH2024ASTMH_1939;    
    Multinomial models adjusted for age, sex, and comorbidities did not report significant differences between the two types of vaccine, regarding the probability of having a severe or moderate case (p>0.05). It is concluded that vaccination with two doses significantly reduces the probability of having a moderate or severe COVID-19 case, and that both types of vaccine have equivalent effectiveness.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Molecular Mechanism-Driven Discovery of Novel Small Molecule Inhibitors against Drug-Resistant SARS-CoV-2 Mpro Variants. (Pubmed Central) -  Oct 10, 2024   
    Under the selective pressure of nirmatrelvir, a peptidomimetic covalent drug targeting SARS-CoV-2 Mpro, various drug-resistant mutations on Mpro have been acquired in vitro...The binding modes referring to NMI-003-Mpro_E166V and NMI-003-Mpro_L50F+E166V were further elucidated at the atomic level. In summary, NMI-003 reported herein is the first compound with activity against E166V and L50F+E166V, which provides a good starting point to design novel antiviral drugs for the treatment of drug-resistant SARS-CoV-2.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Review, Journal:  Long COVID syndrome: An unfolding enigma. (Pubmed Central) -  Oct 9, 2024   
    Several clinical trials are underway for the treatment of long COVID and the results of these are eagerly awaited. Physical and mental rehabilitation at home, at community level or in the hospital setting as appropriate is essential in patients with long COVID.